Novartis, RetinAI to use AI in wet AMD clinical study
Click Here to Manage Email Alerts
Novartis and RetinAI will collaborate on artificial intelligence projects in ophthalmology and digital health, according to a press release.
The first project will support a multicenter international clinical study involving more than 500 patients with wet age-related macular degeneration. The study will investigate the influence of OCT image solutions using AI to assess disease activity, according to the release. RetinAI’s Discovery data management platform will be used to process data at scale across imaging platforms and devices.
“Our Discovery platform and AI tools are enablers to increase efficiency in research and clinical studies, and we expect they can also improve medications and treatments for patients. We believe using RetinAI’s technologies for data from patients treated with ophthalmic medications will provide enhanced disease insights and create opportunities for more precise treatments,” Carlos Ciller, PhD, CEO of RetinAI, said in the release.
Read more about
Click Here to Manage Email Alerts